Phase I/II clinical study of GW572016 (lapatinib ditosylate monohydrate) in combination with trastuzumab in patients with breast cancer previously treated with trastuzumab

Trial Profile

Phase I/II clinical study of GW572016 (lapatinib ditosylate monohydrate) in combination with trastuzumab in patients with breast cancer previously treated with trastuzumab

Completed
Phase of Trial: Phase I/II

Latest Information Update: 20 Jan 2017

At a glance

  • Drugs Lapatinib (Primary) ; Trastuzumab
  • Indications Breast cancer
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 20 May 2011 Actual end date changed from Nov 2008 to Dec 2007 as reported by ClinicalTrials.gov.
    • 14 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Apr 2008 Status changed from recruiting to in progress, according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top